1. Home
  2. VIGL vs CVGI Comparison

VIGL vs CVGI Comparison

Compare VIGL & CVGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIGL
  • CVGI
  • Stock Information
  • Founded
  • VIGL 2020
  • CVGI 2000
  • Country
  • VIGL United States
  • CVGI United States
  • Employees
  • VIGL N/A
  • CVGI N/A
  • Industry
  • VIGL Biotechnology: Pharmaceutical Preparations
  • CVGI Auto Parts:O.E.M.
  • Sector
  • VIGL Health Care
  • CVGI Consumer Discretionary
  • Exchange
  • VIGL Nasdaq
  • CVGI Nasdaq
  • Market Cap
  • VIGL 125.3M
  • CVGI 115.2M
  • IPO Year
  • VIGL 2022
  • CVGI 2004
  • Fundamental
  • Price
  • VIGL $3.40
  • CVGI $3.12
  • Analyst Decision
  • VIGL Buy
  • CVGI Buy
  • Analyst Count
  • VIGL 5
  • CVGI 1
  • Target Price
  • VIGL $16.60
  • CVGI $10.00
  • AVG Volume (30 Days)
  • VIGL 95.3K
  • CVGI 149.8K
  • Earning Date
  • VIGL 11-05-2024
  • CVGI 10-30-2024
  • Dividend Yield
  • VIGL N/A
  • CVGI N/A
  • EPS Growth
  • VIGL N/A
  • CVGI N/A
  • EPS
  • VIGL N/A
  • CVGI 0.94
  • Revenue
  • VIGL N/A
  • CVGI $931,750,000.00
  • Revenue This Year
  • VIGL N/A
  • CVGI N/A
  • Revenue Next Year
  • VIGL N/A
  • CVGI $13.33
  • P/E Ratio
  • VIGL N/A
  • CVGI $3.38
  • Revenue Growth
  • VIGL N/A
  • CVGI N/A
  • 52 Week Low
  • VIGL $2.47
  • CVGI $3.02
  • 52 Week High
  • VIGL $9.24
  • CVGI $7.91
  • Technical
  • Relative Strength Index (RSI)
  • VIGL 48.41
  • CVGI 39.66
  • Support Level
  • VIGL $3.20
  • CVGI $3.02
  • Resistance Level
  • VIGL $3.48
  • CVGI $3.19
  • Average True Range (ATR)
  • VIGL 0.17
  • CVGI 0.16
  • MACD
  • VIGL 0.02
  • CVGI 0.01
  • Stochastic Oscillator
  • VIGL 55.56
  • CVGI 18.18

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

About CVGI Commercial Vehicle Group Inc.

Commercial Vehicle Group Inc is a supplier of cab-related products and systems. Its operating segments are Vehicle Solutions, Industrial Automation, Electrical Systems, and Aftermarket and Accessories. Vehicle Solutions segment designs manufacture and sell Commercial vehicle seats and Plastic components. Warehouse Automation segment designs, manufactures, and sells Warehouse automation subsystems including control panels, electro-mechanical assemblies, cable assemblies, and power and communication solutions. Electrical Systems segment designs, manufactures and sells cable and harness assemblies for both high and low voltage applications, control boxes, dashboard assemblies, and design and engineering for these applications. The company makes majority of its revenue from Vehicle Solutions.

Share on Social Networks: